Jounce Therapeutics, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
780 Memorial Drive, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K/A - Q4 2022 - Apr 28, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 773 % -46.1%
Debt-to-equity 17.5 % +62%
Return On Equity -30.9 % +12.2%
Return On Assets -26.3 % +17.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 52.6M shares +1.88%
Common Stock, Shares, Outstanding 51.7M shares +0.84%
Entity Public Float 125M USD -40.5%
Common Stock, Value, Issued 51K USD 0%
Weighted Average Number of Shares Outstanding, Basic 51.7M shares +3.5%
Weighted Average Number of Shares Outstanding, Diluted 51.7M shares +3.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 103M USD +16.1%
General and Administrative Expense 31M USD +6.85%
Operating Income (Loss) -52.2M USD +42.6%
Income Tax Expense (Benefit) 135K USD +800%
Net Income (Loss) Attributable to Parent -50.9M USD +44%
Earnings Per Share, Basic -0.99 USD/shares +45.6%
Earnings Per Share, Diluted -0.99 USD/shares +45.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 151M USD +57.6%
Assets, Current 197M USD +3.36%
Property, Plant and Equipment, Net 3.72M USD -23.8%
Operating Lease, Right-of-Use Asset 8.6M USD -27.6%
Other Assets, Noncurrent 3M USD -13.1%
Assets 213M USD -15.9%
Accounts Payable, Current 2.1M USD +25.1%
Employee-related Liabilities, Current 6.2M USD -9.35%
Accrued Liabilities, Current 17.1M USD +27.3%
Liabilities, Current 23.6M USD +24.7%
Operating Lease, Liability, Noncurrent 5.87M USD -41.3%
Liabilities 29.4M USD +1.89%
Accumulated Other Comprehensive Income (Loss), Net of Tax -677K USD -184%
Retained Earnings (Accumulated Deficit) -293M USD -21.1%
Stockholders' Equity Attributable to Parent 183M USD -18.2%
Liabilities and Equity 213M USD -15.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.2M USD +1.15%
Net Cash Provided by (Used in) Financing Activities 409K USD -99.6%
Net Cash Provided by (Used in) Investing Activities -2.36M USD +75.5%
Common Stock, Shares Authorized 160M shares 0%
Common Stock, Shares, Issued 51.7M shares +0.84%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -35.1M USD -172%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 152M USD +56.9%
Deferred Tax Assets, Valuation Allowance 98.6M USD +23.2%
Deferred Tax Assets, Gross 101M USD +21.2%
Operating Lease, Liability 10M USD -26.8%
Depreciation 590K USD -24.8%
Payments to Acquire Property, Plant, and Equipment 107K USD -32.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -51.4M USD +43.6%
Lessee, Operating Lease, Liability, to be Paid 11M USD -29.6%
Property, Plant and Equipment, Gross 23.1M USD +0.75%
Operating Lease, Liability, Current 4.15M USD +12.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.94M USD +3.11%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.8M USD +3.11%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 972K USD -49.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.25M USD -74.6%
Deferred Tax Assets, Operating Loss Carryforwards 32.9M USD -27.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 1.16M USD -22.3%
Additional Paid in Capital 477M USD +2.29%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.35M USD -27.6%
Share-based Payment Arrangement, Expense 10.3M USD -10.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%